
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Occupational Health Program, Departments of Environmental Health [W. Z., L. L. X., D. P. M., L. S., D. C. C.] and Biostatistics [S. W. T.], Harvard School of Public Health, Boston, Massachusetts, 02115, and Department of Hematology-Oncology [G. L., T. J. L.] and Pulmonary and Critical Care Unit [D. C. C.], Department of Medicine, and Thoracic Surgery Unit, Department of Surgery [J. C. W.], Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, 02114
N-acetyltrasferase-2 (NAT2) and microsomal epoxide hydrolase (mEH) are polymorphic genes that metabolize different tobacco carcinogens. Smaller studies found inconsistent relationships between NAT2 or mEH polymorphisms and lung cancer risk. To determine whether there is gene-environment interaction between NAT2 polymorphisms, alone or in combination with mEH polymorphisms, and cumulative smoking exposure in the development of lung cancer, we conducted a case control study of 1115 Caucasian lung cancer patients and 1250 spouse and friend controls. The results were analyzed using generalized additive models and logistic regression, adjusting for relevant covariates. There was no overall relationship between NAT2 genotype and lung cancer risk; the adjusted odds ratio (OR) of the rapid versus slow acetylator genotypes was 0.96 [95% confidence interval (CI), 0.791.16]. However, gene-environment interaction analyses revealed that the adjusted ORs increased significantly as pack-years increased. For nonsmokers, the fitted OR was 0.66 (95% CI, 0.440.99), whereas for heavy smokers (80 pack-years), the OR increased to 1.22 (95% CI, 0.891.67). When comparing the extreme genotype combinations of the NAT2 rapid acetylator, higher mEH activity genotype to the NAT2 slow acetylator, and very low mEH activity genotype, the corresponding ORs at 0 and 80 pack-years were 0.30 (95% CI, 0.140.62) and 2.19 (95% CI, 1.263.81), respectively. Results were similar with ORs derived from stratified models. In conclusion, NAT2 rapid acetylator genotypes are protective against lung cancer in nonsmokers but are risk factors in heavy smokers. The joint effects of NAT2 and mEH polymorphisms are consistent with an independent, additive effect of these two genes, modified by smoking history.
This article has been cited by other articles:
![]() |
A. G. Schwartz, G. M. Prysak, C. H. Bock, and M. L. Cote The molecular epidemiology of lung cancer Carcinogenesis, March 1, 2007; 28(3): 507 - 518. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. W. Thurston, G. Liu, D. P. Miller, and D. C. Christiani Modeling Lung Cancer Risk in Case-Control Studies Using a New Dose Metric of Smoking Cancer Epidemiol. Biomarkers Prev., October 1, 2005; 14(10): 2296 - 2302. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Suk, S. Gurubhagavatula, S. Park, W. Zhou, L. Su, T. J. Lynch, J. C. Wain, D. Neuberg, G. Liu, and D. C. Christiani Polymorphisms in ERCC1 and Grade 3 or 4 Toxicity in Non-Small Cell Lung Cancer Patients Clin. Cancer Res., February 15, 2005; 11(4): 1534 - 1538. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Zhou, G. Liu, S. Park, Z. Wang, J. C. Wain, T. J. Lynch, L. Su, and D. C. Christiani Gene-Smoking Interaction Associations for the ERCC1 Polymorphisms in the Risk of Lung Cancer Cancer Epidemiol. Biomarkers Prev., February 1, 2005; 14(2): 491 - 496. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Ryan, W. Huang, S. W Thurston, K. T Kelsey, J. K Wiencke, and D. C Christiani On the use of biomarkers for environmental health research Statistical Methods in Medical Research, June 1, 2004; 13(3): 207 - 225. [Abstract] [PDF] |
||||
![]() |
W. Zhou, G. Liu, D. P. Miller, S. W. Thurston, L. L. Xu, J. C. Wain, T. J. Lynch, L. Su, and D. C. Christiani Polymorphisms in the DNA Repair Genes XRCC1 and ERCC2, Smoking, and Lung Cancer Risk Cancer Epidemiol. Biomarkers Prev., April 1, 2003; 12(4): 359 - 365. [Abstract] [Full Text] [PDF] |
||||
![]() |
G E Goodman Lung cancer * 1: Prevention of lung cancer Thorax, November 1, 2002; 57(11): 994 - 999. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |